Celgene Corporation (CELG) Given “Buy” Rating at Cann

Cann reaffirmed their buy rating on shares of Celgene Corporation (NASDAQ:CELG) in a research note published on Thursday, October 26th.

A number of other research analysts have also issued reports on the company. Morgan Stanley lowered Celgene Corporation from an equal weight rating to an underweight rating and set a $120.00 target price on the stock. in a report on Thursday, October 5th. BTIG Research reaffirmed a hold rating on shares of Celgene Corporation in a report on Sunday, October 22nd. Vetr raised Celgene Corporation from a buy rating to a strong-buy rating and set a $144.39 price target on the stock in a research note on Monday, October 23rd. Citigroup Inc. cut Celgene Corporation from a buy rating to a neutral rating in a research note on Friday, October 20th. Finally, Guggenheim initiated coverage on Celgene Corporation in a research note on Monday, October 23rd. They issued a buy rating and a $160.00 price target on the stock. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. The company has an average rating of Buy and an average target price of $139.64.

Shares of Celgene Corporation (CELG) traded down $0.12 on Thursday, reaching $102.34. The company had a trading volume of 6,473,500 shares, compared to its average volume of 12,623,050. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The company has a market capitalization of $80,574.02, a PE ratio of 15.99, a PEG ratio of 0.79 and a beta of 1.79. Celgene Corporation has a 52-week low of $94.55 and a 52-week high of $147.17.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.58 earnings per share. sell-side analysts predict that Celgene Corporation will post 6.67 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/12/celgene-corporations-celg-buy-rating-reaffirmed-at-cann.html.

In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares in the company, valued at $12,110,599.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock valued at $2,843,956 over the last 90 days. Corporate insiders own 0.95% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Waldron LP increased its stake in shares of Celgene Corporation by 48.9% in the 1st quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock valued at $640,000 after purchasing an additional 1,709 shares during the last quarter. First Trust Advisors LP lifted its stake in shares of Celgene Corporation by 48.1% in the 1st quarter. First Trust Advisors LP now owns 505,993 shares of the biopharmaceutical company’s stock valued at $62,961,000 after purchasing an additional 164,227 shares during the period. Advisors Asset Management Inc. lifted its stake in shares of Celgene Corporation by 6.6% in the 1st quarter. Advisors Asset Management Inc. now owns 75,413 shares of the biopharmaceutical company’s stock valued at $9,384,000 after purchasing an additional 4,674 shares during the period. American Century Companies Inc. lifted its stake in shares of Celgene Corporation by 4.4% in the 1st quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after purchasing an additional 276,089 shares during the period. Finally, Investment Management of Virginia LLC increased its position in Celgene Corporation by 14.2% in the 1st quarter. Investment Management of Virginia LLC now owns 45,733 shares of the biopharmaceutical company’s stock valued at $5,690,000 after buying an additional 5,685 shares in the last quarter. Hedge funds and other institutional investors own 78.92% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply